Tapinarof Nanogels as a Promising Therapeutic Approach
Open Access
- 1 June 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (6) , 731
Abstract
Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.Keywords
Funding Information
- Ministry of Culture and Innovation of Hungary (TKP2021-EGA-18, 2022-1.2.2-TÉT-IPARI-UZ-2022-00006)
- TKP2021-EGA funding scheme (TKP2021-EGA-18, 2022-1.2.2-TÉT-IPARI-UZ-2022-00006)
- Gedeon Richter Excellence PhD Scholarship of Gedeon Richter (TKP2021-EGA-18, 2022-1.2.2-TÉT-IPARI-UZ-2022-00006)
This publication has 125 references indexed in Scilit:
- Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenDermatology and Therapy, 2025
- Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc AnalysesDermatology and Therapy, 2024
- Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical TrialsDermatology and Therapy, 2024
- The Immunology of Psoriasis—Current Concepts in PathogenesisClinical Reviews in Allergy & Immunology, 2024
- A Review on Nanosystem-Based Delivery of Tofacitinib for Enhanced Treatment of Autoimmune Diseases and InflammationBioNanoScience, 2024
- A Novel Methacryloyl Chitosan Hydrogel Microneedles Patch with Sustainable Drug Release Property for Effective Treatment of PsoriasisMacromolecular Bioscience, 2023
- Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USADermatology and Therapy, 2023
- Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat PsoriasisDermatology and Therapy, 2022
- Nanotechnology for Psoriasis TherapyCurrent Dermatology Reports, 2019
- Ixekizumab: A Review in Moderate to Severe Plaque PsoriasisAmerican Journal of Clinical Dermatology, 2017